证券代码：603566 证券简称：普莱柯 公告编号：2024-020 普莱柯生物工程股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、召开会议的基本情况 (一)股东大会类型和届次 2023 年年度股东大会 (四)现场会议召开的日期、时间和地点 召开的日期时间：2024 年 5 月 16 日 14 点 00 分 召开地点：河南省洛阳市洛龙区政和路 15 号公司二楼会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 5 月 16 日 至 2024 年 5 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 股东大会召开日期：2024年5月16日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二)股东大会召集人：董事 ...

普莱柯生物工程股份有限公司 2023年度独立董事述职报告 (魏刚) 2023 年度,作为普莱柯生物工程股份有限公司(以下简称"公司"）的独 立董事,本人严格按照《中华人民共和国公司法》《上市公司治理准则》《上市 公司独立董事管理办法》《上海证券交易所股票上市规则》《上海证券交易所上 市公司自律监管指引第1号—规范运作》以及《公司章程》《独立董事工作制度》 等有关规定,勤勉尽责,在董事会日常工作及重要决策中忠实履行独立董事的职 责和义务,认真审议各项议案,从公司整体利益出发,维护了公司和全体股东特 别是中小股东的合法权益。现将本人在 2023 年度（2023 年 1 月 1 日至 2023 年 4 月 11 日) 履职情况报告如下: 1 本人于 2020 年 2 月 26 日至 2023 年 4 月 11 日期间担任公司第四届董事会独 立董事职务,兼任公司第四届董事会审计委员会主任委员、第四届董事会提名委 员会委员、第四届董事会薪酬与考核委员会委员。作为公司的独立董事、本人具 备独立董事任职资格和《上市公司独立董事管理办法》所要求的独立性,不在公 司担任除独立董事以外的其他职务，不存在影响独立性的情况。 二、2 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥235,489,193.20, representing a decrease of 23.27% compared to the same period last year[3] - The net profit attributable to shareholders was ¥27,307,052.31, down 57.36% year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥26,535,800.53, a decrease of 56.10% compared to the previous year[3] - The company reported a net profit of CNY 30,309,849.97 for Q1 2024, compared to a net profit of CNY 65,853,381.34 in Q1 2023, indicating a decline in profitability[20] - The net profit for Q1 2024 is CNY 27,307,052.31, a decrease of 57.4% compared to CNY 64,039,214.39 in Q1 2023[21] - Operating profit for Q1 2024 is CNY 31,185,610.68, down from CNY 75,288,713.97 in the same period last year, representing a decline of 58.6%[21] - The total profit for Q1 2024 is CNY 31,064,720.71, down from CNY 75,365,391.43 in Q1 2023, reflecting a decrease of 58.8%[21] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥4,394,457.00, reflecting a decline of 113.66%[3] - Cash flow from operating activities for Q1 2024 is negative at CNY -4,394,457.00, compared to a positive CNY 32,169,320.98 in Q1 2023[25] - The cash flow from investment activities is negative at CNY -95,695,591.48 for Q1 2024, compared to a positive CNY 6,868,985.95 in Q1 2023[25] - The total cash and cash equivalents at the end of Q1 2024 is CNY 193,951,219.06, a decrease from CNY 303,902,530.58 at the end of Q1 2023[26] - Cash and cash equivalents decreased to CNY 198,455,275.70 as of March 31, 2024, from CNY 317,214,603.27 at the end of 2023, indicating liquidity challenges[15] Revenue Breakdown - Revenue from the biological products segment was ¥167,801,488.57, down 9.64% year-on-year, with swine vaccines declining by 25.08%[5] - The revenue from chemical drugs was ¥53,983,997.26, a significant drop of 52.80% compared to the previous year[5] - The company reported a significant decrease in sales revenue from CNY 333,504,750.28 in Q1 2023 to CNY 242,447,918.40 in Q1 2024, a decline of 27.3%[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,205,137,124.84, a decrease of 1.75% from the end of the previous year[4] - Total assets as of March 31, 2024, were CNY 3,205,137,124.84, down from CNY 3,262,208,830.69 at the end of 2023[18] - Total liabilities decreased to CNY 471,723,911.92 as of March 31, 2024, from CNY 538,334,059.46 at the end of 2023, showing improved financial stability[17] Cost and Expenses - Total operating costs for Q1 2024 were CNY 205,179,343.23, down 14.9% from CNY 241,057,359.58 in Q1 2023[20] - Gross profit margin for Q1 2024 was approximately 10.8%, compared to 21.3% in Q1 2023[20] - Research and development expenses increased to CNY 20,460,399.77 in Q1 2024, up from CNY 17,441,000.70 in Q1 2023, reflecting a focus on innovation[20] Other Financial Metrics - The company reported a basic earnings per share of ¥0.08, down 57.89% from the same period last year[3] - Basic and diluted earnings per share for Q1 2024 are both CNY 0.08, down from CNY 0.19 in Q1 2023[22] - The weighted average return on net assets was 1.00%, a decrease of 1.26 percentage points[3] - The company experienced a 37.44% decrease in cash and cash equivalents, primarily due to increased payments for engineering projects[8] - Inventory levels increased to CNY 187,061,605.45 as of March 31, 2024, from CNY 183,619,075.92 at the end of 2023, suggesting potential overstocking[16] - The total cash inflow from investment activities in Q1 2024 is CNY 298,979,127.45, down from CNY 872,264,903.19 in Q1 2023, a decrease of 65.7%[25]

一、监事会日常工作情况 2023 年度，公司监事会共召开了 7 次会议。监事会的召集、召开以及监事 权利的行使符合《公司法》《公司章程》和《监事会议事规则》的相关规定。具 体情况如下： 普莱柯生物工程股份有限公司 2023 年度监事会工作报告 2023 年，普莱柯生物工程股份有限公司（以下简称"公司"）监事会严格按 照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）等相关法律法规及《公司章程》和公司《监事会议事 规则》的要求，谨慎、认真地履行职责，依法独立行使职权。监事会成员列席公 司召开的董事会，参加了公司召开的股东大会，从切实维护公司利益和股东权益 的角度出发，对公司重大决策和决议的形成、表决程序进行了监督和审查，对公 司规范运作、内部控制、财务工作、董事和高管履职、控股子公司的经营情况等 进行了监督检查，为公司规范运作和健康发展提供了有力保障。现将监事会 2023 年主要工作情况报告如下： 1、公司于 2023 年 1 月 15 日召开第四届监事会第二十次会议，审议通过了 如下议案： （1）关于预计 2023 年度日常关联交易的议案。 2、公司于 ...

证券代码：603566 证券简称：普莱柯 公告编号：2024-018 普莱柯生物工程股份有限公司 关于 2023 年度计提资产减值准备的公告 2023 年，公司计提信用减值损失和资产减值损失共计 2,389.00 万元，明细 如下： 单位：元 | | 项目 | 2023 年度计提金额 | | | --- | --- | --- | --- | | | 应收票据坏账损失 | | -4,333,606.89 | | 信用减值损失 | 应收账款坏账损失 | | 27,663,536.86 | | | 其他应收款坏账损失 | | 527,825.78 | | 资产减值损失 | 固定资产减值损失 | | 32,216.47 | | | 合计 | | 23,889,972.22 | 二、本次计提资产减值准备的具体说明 （一）信用减值损失 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 普莱柯生物工程股份有限公司（以下简称"公司"）根据《上海证券交易所 股票上市规则》《企业会计准则》和公司会计政策等相关规定，基于谨慎性原则， 对截至 202 ...

普莱柯生物工程股份有限公司 董事会审计委员会对会计师事务所 2023 年度 履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》《上海证券交易所上 市公司自律监管指引第 1 号——规范运作》和《公司章程》等规定和要求，普 莱柯生物工程股份有限公司（以下简称"公司"）董事会审计委员会本着勤勉尽 责的原则，恪尽职守，认真履职。现将董事会审计委员会对会计师事务所 2023 年度履行监督职责的情况汇报如下： 一、2023 年年审会计师事务所基本情况 （一）会计师事务所基本情况 立信会计师事务所（特殊普通合伙）（以下简称"立信"）由我国会计泰斗 潘序伦博士于 1927 年在上海创建，1986 年复办，2010 年成为全国首家完成改制 的特殊普通合伙制会计师事务所，注册地址为上海市，首席合伙人为朱建弟先生。 立信是国际会计网络 BDO 的成员所，长期从事证券服务业务，新证券法实施前 具有证券、期货业务许可证，具有 H 股审计资格，并已向美国公众公司会计监 督委员会（PCAOB）注册登记。 截至 2023 年末，立信拥有合伙人 27 ...

普莱柯生物工程股份有限公司 2023年度独立董事述职报告 (邹欣) 2023 年度,作为普莱柯生物工程股份有限公司(以下简称"公司")的独 立董事,本人严格按照《中华人民共和国公司法》《上市公司治理准则》《上市 公司独立董事管理办法》《上海证券交易所股票上市规则》《上海证券交易所上 市公司自律监管指引第1号-规范运作》以及《公司章程》《独立董事工作制度》 等有关规定,勤勉尽责,在董事会日常工作及重要决策中忠实履行独立董事的职 责和义务,认真审议各项议案,从公司整体利益出发,维护了公司和全体股东特 别是中小股东的合法权益。现将本人在 2023年度(2023年1月1日至2023年4 月 11日)履职情况报告如下: 一、独立董事的基本情况 1、独立董事人员情况 公司第四届董事会任期届满,于2023年4月11日选举产生了第五届董事会 非独立董事和独立董事。 第四届董事会独立董事 3人,分别为:邹欣女士、魏刚先生、张波先生; 第五届董事会独立董事3人,分别为:曹永长先生、王楚端先生、张宪胜先 生。 2、独立董事个人简历及独立性情况说明 本人邹欣,博士学历,教授职称。历任中国财政科学研究院博士后、山东省 工会干部管理学院 ...

Financial Performance - The company's operating revenue for 2023 reached CNY 1,252,693,603, representing a year-on-year increase of 1.84% compared to CNY 1,099,118,746 in 2022[19]. - The net profit attributable to shareholders was CNY 174,517,388.93, reflecting a growth of 3.99% from CNY 238,846,405 in the previous year[19]. - The basic earnings per share decreased to CNY 0.50, down 3.85% from CNY 0.76 in 2022[20]. - The cash flow from operating activities for 2023 was CNY 282,777,239.58, an increase of 23.83% compared to CNY 212,533,722 in 2022[19]. - The company's net assets attributable to shareholders decreased by 2.86% to CNY 2,723,874,771.23 from CNY 2,803,974,341.41 in the previous year[19]. - The company reported a total revenue of CNY 769.18 million from direct sales, with a gross margin of 65.69%, which decreased by 3.49 percentage points compared to the previous year[58]. - The company’s total sales revenue for 2023 was approximately 1,242,579,840.52 RMB, showing an increase from 1,217,004,307.01 RMB in 2022[92]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in 2023, representing a 20% growth year-over-year[132]. Dividends and Shareholder Returns - The company plans to distribute a cash dividend of RMB 4.00 per 10 shares, totaling an estimated cash dividend of RMB 138,281,309.20 (including tax) based on the total share capital as of December 31, 2023[5]. - The company declared a cash dividend of 4.00 CNY per 10 shares, totaling 138,281,309.20 CNY, which represents 79.24% of the net profit attributable to ordinary shareholders[156]. - The total amount of cash dividends distributed, including share repurchases, is 145,924,327.20 CNY, accounting for 83.62% of the net profit attributable to ordinary shareholders[156]. Audit and Compliance - The company received a standard unqualified audit report from Lixin Certified Public Accountants[4]. - There are no non-operating fund occupations by controlling shareholders or related parties, and no violations in decision-making procedures for external guarantees[7]. - The company has a complete independent accounting system and financial management structure[120]. - The company has not faced any significant legal or regulatory discrepancies in its governance practices[120]. - The company has not faced any penalties from securities regulatory agencies in the past three years[137]. Research and Development - The company’s R&D investment reached 101.1 million yuan, accounting for 8.07% of revenue, with three new veterinary drug registrations obtained, including a vaccine that fills a domestic gap[33]. - The company has established several national-level research platforms, including the National Veterinary Drug Engineering Technology Research Center and the National Enterprise Technology Center, enhancing its R&D capabilities[42]. - The company is focused on innovation, with a strong emphasis on developing gene-engineered vaccines and multi-valent vaccines, which are well-received by users[40]. - The company has a robust pipeline of products awaiting regulatory approval, indicating a strong future growth potential[87]. - The company is investing $50 million in R&D for new technologies aimed at enhancing user experience and product efficiency[181]. Market Expansion and Strategy - The company is focused on expanding its market presence and developing new products, including vaccines and veterinary drugs[11]. - The company aims to drive innovation in the livestock industry through new technologies and products, focusing on animal health and food safety[50]. - The company is actively pursuing market expansion strategies, particularly in the veterinary pharmaceutical sector, to enhance its competitive position[87]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[132]. - The company is exploring potential mergers and acquisitions to bolster its market position and diversify its product offerings[128]. Governance and Management - The board of directors consists of 9 members, including 3 independent directors, and held 12 meetings during the reporting period[120]. - The company maintained strict independence from its controlling shareholder, with no interference in decision-making or operations[122]. - The management team has been restructured, with new appointments aimed at enhancing operational efficiency and strategic direction[127]. - The company has implemented measures to ensure transparency and timely information disclosure[121]. - The company is undergoing a board restructuring with several new appointments and elections to enhance governance[136]. Environmental and Social Responsibility - The company has invested 12.2252 million CNY in environmental protection during the reporting period[162]. - The company has complied with environmental regulations, with all pollution control facilities operating effectively and meeting discharge standards[166]. - The company has developed emergency response plans for environmental incidents and conducted regular training and drills for employees[168]. - The company emphasizes environmental protection during production, ensuring wastewater is treated effectively before discharge and meeting emission standards for gas[175]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[171]. Risks and Challenges - The company faces risks from animal diseases that could impact the livestock industry, but its diverse product range helps mitigate these risks[112]. - Regulatory risks are increasing due to stricter government policies on veterinary drug development and sales, which may affect operational goals[113]. - The competitive landscape is intensifying as the livestock and pet industries grow, prompting the company to enhance product and technology upgrades[114]. - The company acknowledges the risks associated with product development, including potential delays and failures in vaccine registration processes[115].

普莱柯生物工程股份有限公司 董事会审计委员会 2023 年度履职情况报告 三、董事会审计委员会主要工作内容 1、监督和评估外部审计机构工作 普莱柯生物工程股份有限公司（以下简称"公司"）董事会审计委员会按照中 国证监会《上市公司治理准则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》和公司相关制度的要求，本着勤勉尽责的原则，认真履行职责， 充分发挥了审查和监督的作用，为完善内部控制、提高财务报告质量发挥了重要 作用。现就 2023 年度审计委员会工作情况向董事会作如下报告： 一、审计委员会基本情况 报告期内，公司第四届董事会审计委员会由独立董事魏刚先生、独立董事张 波先生和董事宋永军先生共同组成，其中主任委员由具有专业会计资格的魏刚先 生担任。2023 年 4 月 11 日，经公司 2023 年第一次临时股东大会审议通过第五 届董事会及其专门委员会的换届选举相关事项，其中选举独立董事张宪胜先生、 独立董事王楚端先生、董事赵锐先生担任第五届董事会审计委员会成员，其中主 任委员由具有专业会计资格的独立董事张宪胜先生担任。 根据《上市公司独立董事管理办法》（证监会令〔第 220 号〕）等相关规定， 公 ...

普莱柯生物工程股份有限公司 募集资金存放与使用情况 专项报告的鉴证报告 二○二三年度 关于普莱柯生物工程股份有限公司2023年度募集资金存放 与使用情况专项报告的鉴证报告 信会师报字[2024]第ZA11755号 普莱柯生物工程股份有限公司全体股东： 我们接受委托，对后附的普莱柯生物工程股份有限公司（以下简 称"普莱柯"） 2023年度募集资金存放与使用情况专项报告（以下简 称"募集资金专项报告"）执行了合理保证的鉴证业务。 一、董事会的责任 普莱柯董事会的责任是按照中国证券监督管理委员会《上市公司 监管指引第2号——上市公司募集资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15号）、《上海证券交易所上市公 司自律监管指引第1号——规范运作》以及《上海证券交易所上市公 司自律监管指南第1号——公告格式》的相关规定编制募集资金专项 报告。这种责任包括设计、执行和维护与募集资金专项报告编制相关 的内部控制，确保募集资金专项报告真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏。 二、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对募集资金专项报告发 表鉴证结论。 三、工作概述 ...